Xiangxue Pharmaceutical Co.Ltd(300147) (300147) announced on December 24 that the company plans to transfer 53% of the equity of Xiangxue Asia to Yingqian and 10% of the equity of Xiangxue Asia to nanyeying yuan, with a total transfer price of 81.9 million yuan. After the implementation of the transaction, Xiangxue Asia will no longer be included in the scope of the company’s consolidated statements. In addition, in order to optimize the asset liability structure of Xiangxue smart TCM, a wholly-owned subsidiary of the company, the company will increase its capital by RMB 100 million in cash based on the registered capital of Xiangxue smart TCM. After the capital increase, the registered capital of Xiangxue smart TCM will increase from RMB 160 million to RMB 260 million.
(Securities Times)
